摘要
目的 综合分析含莫西沙星的三联方案作为根除幽门螺杆菌（Hp）一线方案的疗效.方法 检索比较含莫西沙星的三联方案和标准三联方案根除幽门螺杆菌治疗的随机对照临床试验,进行荟萃分析.结果 共有7项随机对照试验符合人选标准,共纳入899例患者.基于意向治疗分析的结果显示含莫西沙星组Hp根除率为85.7%,标准治疗组为74.7%,差异有显著性（P〈0.0001）.基于按符合方案集分析的结果显示含莫西沙星组Hp根除率为86.5%,标准治疗组为76.1%,差异有显著性（P〈0.0001）.进一步行敏感性分析显示,纳入高质量研究、中文研究、疗程7天的研究和不同疾病谱的研究时结果均未出现变化.结论 含莫西沙星的三联治疗方案有较高的Hp根除率,且优于目前的标准治疗方案,可以作为根除Hp的一线治疗方案.
Objective To systematically review the efficacy of moxifloxaein-based triple therapy for Helicohacter pylori （Hp） eradication. Methods ： Randomized controlled trials （RCT） comparing moxifloxacin-based triple therapy with standard triple therapy were searched for meta-analysis. Results Seven RCTs met the inclusion criteria and 899 patients were included. Meta-analysis based on intention-to-treat analysis showed that eradication rates of moxifloxacin-based therapy and standard triple therapy were 85.7% and 74.7%, respectively （ OR 2.08,95% CI ： 1.47-2.93, P 〈 0. 0001 ）. Meta-analysis based on per-protocol analysis showed that eradication rates of moxifloxacin-based therapy and standard triple therapy were 86.5% and 76. 1% , respectively （ OR 2.08,95 % CI： 1.45-2.96, P 〈 0. 0001 ）. When including high quality studies, Chinese studies, the studies of the 7d course and the studies involving different diseases, eradication rates of moxileloxacin-based therapy were also higher than those of standard triple therapy. Conclusions Moxifloxacin-based triple therapy had high eradication rate for Hp infection, and was superlor to standard triple therapy.
出处
《临床内科杂志》
CAS
2010年第11期748-750,共3页
Journal of Clinical Internal Medicine
关键词
莫西沙星
幽门螺杆菌
荟萃分析
Moxifloxacin
Helicobacter pylori
Meta-analysis
